Here we have a short guide to Aplos NCA process of uploading data, configuring settings, and retrieving results.
Aplos Analytics Resource Hub: Your Guide to Mastering Our Platform
Welcome to the Aplos NCA Resource Center! This is your go-to space for all things Aplos NCA, where you'll find a variety of video tutorials and guides to help you navigate and make the most of our platform.
FROM VISION TO REALITY
Interviews with our founders
From Vision to Reality: Nathan Teuscher - President and Founder
A concise and insightful interview with our Founder and President, Nathan Teuscher, exploring the journey behind Aplos Analytics, the challenges shaping the pharmacokinetics industry, and the exciting updates on the horizon.
Analyze single dose and steady state data together
Users can now analyze single dose and steady-state data in a single analysis by using a data column to define the dosing frequency. The selected column should contain “single” if the data is associated with a single dose, or “steady-state” if the data is associated with a steady-state dose. Aplos NCA will read the first record for each unique profile and then use that information to calculate either single dose or steady-state parameters.
Analyze Data from multiple routes of administration in a single analysis
Users can now analyze data from different routes of administration in a single analysis by using a data column to define the type of dose. The selected column should contain “ev” if the dose is extravascular, “iv-bolus” if the dose is an IV bolus, and “iv-infusion” if the dose is an IV infusion.
Analyze single dose and steady state data together
Users can now analyze single dose and steady-state data in a single analysis by using a data column to define the dosing frequency. The selected column should contain “single” if the data is associated with a single dose, or “steady-state” if the data is associated with a steady-state dose. Aplos NCA will read the first record for each unique profile and then use that information to calculate either single dose or steady-state parameters.
Calculate Partial AUCs
Users can now define partial AUC values for calculation during analysis. Users can specify the start and stop time for each partial AUC to be calculated. Users also specify the parameter name and parameter code to be included in the output files. Users can specify as many partial AUC values as needed.
Analyse 30,000 PK profile
An overview of how Aplos Analytics can calculate PK parameters and generate individual plots in linear, semi-log, and semi-log with terminal slope formats analysis. Throughput was 2,000 profiles per minute or 33 profiles per second Scaling up to accommodate more profiles is feasible.
Overview of Aplos NCA
In this video, we provide a comprehensive overview of Aplos NCA, highlighting its core features and functionality. You'll discover how to navigate key aspects of the tool, including allocation counts, configuration settings, validation history, and input data sets.
Different Data Set Formats
In this tutorial, we dive into analyzing different data sets. We'll walk you through each step— focusing on the configuration settings, This step-by-step guide is designed to make the configuration process clear and easy to understand.
Uploading Data
In this video, we cover everything you need to know about uploading data sets in Aplos NCA. We explore the two different upload methods and guide you through the process of retrieving your results.
Validation
Validation is a key priority for us at Aplos! In this video, we guide you through the validation option and history as well as the detailed validation reports available within the platform.
Quick Guide
Reset Password
In this video, we walk you through the essential steps for setting and resetting your password.
FROM VISION TO REALITY
Interviews with our founders
From Vision to Reality: Eric Wilson—CTO and Co-Founder
A concise and insightful interview with our Founder and President, Nathan Teuscher, exploring the journey behind Aplos Analytics, the challenges shaping the pharmacokinetics industry, and the exciting updates on the horizon.